Should I buy or sell IDEAYA Biosciences stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDYA shares. View IDYA analyst ratings or view top-rated stocks .

What is IDEAYA Biosciences' stock price target for 2024?

13 Wall Street analysts have issued 12-month price targets for IDEAYA Biosciences' shares. Their IDYA share price targets range from $24.00 to $60.00. On average, they predict the company's share price to reach $44.55 in the next year. This suggests a possible upside of 19.4% from the stock's current price. View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts .

How have IDYA shares performed in 2024?

IDEAYA Biosciences' stock was trading at $35.58 at the beginning of the year. Since then, IDYA stock has increased by 4.8% and is now trading at $37.30. View the best growth stocks for 2024 here .

Are investors shorting IDEAYA Biosciences?

IDEAYA Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,410,000 shares, an increase of 6.7% from the March 15th total of 8,820,000 shares. Based on an average daily volume of 905,000 shares, the days-to-cover ratio is currently 10.4 days. Currently, 14.3% of the shares of the stock are short sold. View IDEAYA Biosciences' Short Interest .

When is IDEAYA Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our IDYA earnings forecast .

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its earnings results on Tuesday, February, 20th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.05. The business earned $3.90 million during the quarter, compared to analyst estimates of $8.84 million. IDEAYA Biosciences had a negative net margin of 483.05% and a negative trailing twelve-month return on equity of 23.00%. The firm's revenue for the quarter was down 3.0% on a year-over-year basis.

What ETFs hold IDEAYA Biosciences' stock?

ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , ALPS Medical Breakthroughs ETF (SBIO) , Jacob Forward ETF (JFWD) , Loncar China Biopharma ETF (CHNA) , SPDR S&P Biotech ETF (XBI) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU) . iShares Micro-Cap ETF (IWC) .

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX) , Fulcrum Therapeutics (FULC) , OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Boeing (BA) , Xeris Biopharma (XERS) , Entasis Therapeutics (ETTX) , Livongo Health (LVGO) and NVIDIA (NVDA) .

When did IDEAYA Biosciences IPO?

IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:IDYA

IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free IDYA Stock Alerts

$37.02

-0.60 (-1.59%)

(As of 12:38 PM ET)

Compare

Today's Range: $36.98
▼
$38.30
50-Day Range: $37.62
▼
$47.13
52-Week Range: $14.33
▼
$47.74

Volume: 159,126 shs
Average Volume: 848,216 shs
Market Capitalization: $2.76 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.55

Get IDEAYA Biosciences alerts:

IDEAYA Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 19.4% Upside
$44.55 Price Target
Short Interest: Bearish
14.29% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.79
Upright™ Environmental Score
News Sentiment: 0.75
Based on 5 Articles This Week
Insider Trading: Selling Shares
$1.25 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.26) to ($2.63) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.45 out of 5 stars

Medical Sector

275th out of 918 stocks

Pharmaceutical Preparations Industry

114th out of 423 stocks

3.5

Analyst's Opinion

Consensus Rating
IDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
IDEAYA Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
14.29% of the float of IDEAYA Biosciences has been sold short.
Short Interest Ratio / Days to Cover
IDEAYA Biosciences has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
Change versus previous month
Short interest in IDEAYA Biosciences has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
IDEAYA Biosciences does not currently pay a dividend.
Dividend Growth
IDEAYA Biosciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IDEAYA Biosciences has received a 72.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for IDEAYA Biosciences is -0.79.

2.6

News and Social Media Coverage

News Sentiment
IDEAYA Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for IDEAYA Biosciences this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for IDYA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,248,886.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of IDEAYA Biosciences is held by insiders.
Percentage Held by Institutions
98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($2.26) to ($2.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IDEAYA Biosciences is -18.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IDEAYA Biosciences is -18.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IDEAYA Biosciences has a P/B Ratio of 3.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About IDEAYA Biosciences Stock (NASDAQ:IDYA)

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDYA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IDYA Stock News Headlines

April 18, 2024 | americanbankingnews.com

Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Increases By 6.7%

April 10, 2024 | americanbankingnews.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Buy" from Analysts

April 19, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)

April 5, 2024 | prnewswire.com

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 1, 2024 | prnewswire.com

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event

March 20, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - IDYA

March 13, 2024 | markets.businessinsider.com

Strong Buy Rating for IDEAYA Biosciences Based on Strategic Partnership and Promising Oncology Pipeline

March 12, 2024 | seekingalpha.com

Ideaya inks clinical trial pact with Merck

April 19, 2024 | DTI (Ad)

Here’s how to start a “Weekend Side Hustle” from your sofa

Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.

March 12, 2024 | msn.com

Ideaya gains after clinical trial pact with Merck

March 12, 2024 | markets.businessinsider.com

IDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With KEYTRUDA In Endometrial Cancer

March 12, 2024 | prnewswire.com

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

March 10, 2024 | benzinga.com

IDEAYA Biosciences Stock (NASDAQ:IDYA), Quotes and News Summary

March 8, 2024 | markets.businessinsider.com

Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews

March 4, 2024 | prnewswire.com

IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events

February 26, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD)

February 24, 2024 | msn.com

IDEAYA Biosciences (IDYA) Price Target Increased by 28.90% to 51.57

February 23, 2024 | finance.yahoo.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent Results

February 21, 2024 | markets.businessinsider.com

The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 6 Experts

February 20, 2024 | realmoney.thestreet.com

Ideaya Biosciences price target raised by $10 at Oppenheimer, here's why

February 20, 2024 | benzinga.com

Recap: IDEAYA Biosciences Q4 Earnings

February 20, 2024 | markets.businessinsider.com

IDEAYA Biosciences Q4 Results Misses Estimates

February 20, 2024 | finance.yahoo.com

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

February 20, 2024 | prnewswire.com

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

February 16, 2024 | seekingalpha.com

Ideaya Biosciences: A Strong Bet In Targeted Oncology

February 15, 2024 | finance.yahoo.com

IDYA Apr 2024 35.000 put

February 15, 2024 | finance.yahoo.com

IDYA Apr 2024 45.000 put

See More Headlines

Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IDYA
CUSIP: N/A
CIK: 1676725
Web: www.ideayabio.com
Phone: (650) 443-6209
Fax: N/A
Employees: 124
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $44.55
High Stock Price Target: $60.00
Low Stock Price Target: $24.00
Potential Upside/Downside: +18.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,960,000.00
Net Margins: -483.05%
Pretax Margin: -483.05%
Return on Equity: -23.00%
Return on Assets: -21.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.65
Quick Ratio: 19.65

Sales & Book Value

Annual Sales: $23.39 million
Price / Sales: 119.92
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.64 per share
Price / Book: 3.90

Miscellaneous

Outstanding Shares: 74,560,000
Free Float: 70,757,000
Market Cap: $2.80 billion
Optionable: Optionable
Beta: 0.80

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Yujiro S. Hata (Age 50)
President, CEO & Director
Comp: $851.7k
Dr. Michael A. White Ph.D. (Age 58)
Chief Scientific Officer
Comp: $613.85k
Dr. Darrin M. Beaupre M.D. (Age 57)
Ph.D., Chief Medical Officer
Comp: $152.64k
Mr. Andres Ruiz Briseno CPA (Age 37)
Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations
Dr. Paul A. Barsanti Ph.D.
Chief Technology Officer
Mr. Jason S. Throne Esq. (Age 52)
J.D., Chief Legal Officer & Company Secretary
Comp: $425.56k
Mr. Mick O'Quigley
Chief of Staff & Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IDYA Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEAYA Biosciences stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings or view top-rated stocks.
What is IDEAYA Biosciences' stock price target for 2024?: 13 Wall Street analysts have issued 12-month price targets for IDEAYA Biosciences' shares. Their IDYA share price targets range from $24.00 to $60.00. On average, they predict the company's share price to reach $44.55 in the next year. This suggests a possible upside of 19.4% from the stock's current price.
View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts.
How have IDYA shares performed in 2024?: IDEAYA Biosciences' stock was trading at $35.58 at the beginning of the year. Since then, IDYA stock has increased by 4.8% and is now trading at $37.30.
View the best growth stocks for 2024 here.
Are investors shorting IDEAYA Biosciences?: IDEAYA Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,410,000 shares, an increase of 6.7% from the March 15th total of 8,820,000 shares. Based on an average daily volume of 905,000 shares, the days-to-cover ratio is currently 10.4 days. Currently, 14.3% of the shares of the stock are short sold.
View IDEAYA Biosciences' Short Interest.
When is IDEAYA Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our IDYA earnings forecast.
How were IDEAYA Biosciences' earnings last quarter?: IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its earnings results on Tuesday, February, 20th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.05. The business earned $3.90 million during the quarter, compared to analyst estimates of $8.84 million. IDEAYA Biosciences had a negative net margin of 483.05% and a negative trailing twelve-month return on equity of 23.00%. The firm's revenue for the quarter was down 3.0% on a year-over-year basis.

What ETFs hold IDEAYA Biosciences' stock?: ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Jacob Forward ETF (JFWD), Loncar China Biopharma ETF (CHNA), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).iShares Micro-Cap ETF (IWC).
What other stocks do shareholders of IDEAYA Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).
When did IDEAYA Biosciences IPO?: IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.
How do I buy shares of IDEAYA Biosciences?: Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IDYA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial